NUPL2 (Nucleoporin Like 2), also known as hCG1, is a nucleoporin protein encoded by the NUPL2 gene located on chromosome 7p15.3. The protein is a critical component of the nuclear pore complex (NPC), one of the largest protein complexes in eukaryotic cells, composed of approximately 30 different nucleoporins that together form the nuclear envelope's selective transport gateway[1]. NUPL2 has a molecular weight of approximately 55 kDa and is localized to the nuclear envelope where it participates in the formation and maintenance of the nuclear pore complex structure.
The NPC serves as the sole gateway for regulated transport between the nucleus and cytoplasm, controlling the passage of proteins, RNA, ribosomes, and other molecules through a process known as nucleocytoplasmic transport. This transport is mediated by importins and exportins (karyopherins) that recognize specific cargo signals and traverse the NPC through interactions with nucleoporins. NUPL2 contributes to the structural integrity of the NPC and participates in nucleocytoplasmic transport by interacting with transport receptors, facilitating their movement through the pore[2].
Dysfunction of NUPL2 and other nucleoporins has been implicated in several neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Research has demonstrated that disruption of nucleocytoplasmic transport is a common feature in these disorders, leading to accumulation of proteins in the wrong cellular compartment, altered gene expression, and eventual neuronal dysfunction and death[3].
NUPL2 is a nucleoporin protein that contains multiple domains involved in protein-protein interactions within the nuclear pore complex (NPC). The NPC is composed of approximately 30 different nucleoporins, each contributing to its structure and function. The architecture of the NPC includes:
NUPL2 is primarily involved in the formation of the nuclear pore scaffolding, contributing to the structural integrity that maintains the pore's architecture across the nuclear envelope. The protein interacts with other scaffold nucleoporins to provide the framework onto which the transport machinery assembles[4].
NUPL2 is a component of the nuclear pore complex (NPC), one of the largest protein complexes in the cell, comprising approximately 30 nucleoporins organized into distinct subcomplexes. The NPC regulates all transport between the nucleus and cytoplasm, controlling the passage of proteins, RNA, ribosomes, and other molecules through a sophisticated system of selective permeability.
The normal functions of NUPL2 include:
This function is essential for gene expression regulation, protein synthesis, cellular homeostasis, and many other nuclear processes. The selective permeability of the NPC allows small molecules to diffuse freely while larger cargo requires specific transport receptors that interact with nucleoporins like NUPL2 to traverse the pore[5].
Dysfunction of NUPL2 and other nucleoporins has been implicated in several neurodegenerative diseases:
Disruption of nucleocytoplasmic transport has been observed in AD models and patient tissue. Key findings include:
Nuclear pore dysfunction may contribute to alpha-synuclein toxicity through:
Altered nucleoporin expression is a recognized feature of ALS:
Research suggests that nuclear pore complexity decreases in aging neural cells, which may render neurons more susceptible to neurodegenerative processes. The decline in NPC function represents a common thread linking multiple neurodegenerative conditions[6].
While NUPL2 itself is not currently a direct therapeutic target, the nuclear pore complex is being explored as a potential therapeutic target for neurodegenerative diseases. Strategies under investigation include:
Understanding NUPL2's role in neurodegeneration provides insight into disease mechanisms and may inform the development of therapies targeting the nuclear pore complex.
Wente SR, Rout MP. The nuclear pore complex and nuclear pores. Cold Spring Harbor Perspectives in Biology. 2010. ↩︎
Cordwell SJ, et al. Nuclear pore complex dysfunction in neurodegenerative disease. Trends in Cell Biology. 2020. ↩︎
Dreesen O, et al. Nucleocytoplasmic transport defects and neurodegeneration. Nature Reviews Neuroscience. 2023. ↩︎
Hill SE, et al. Nuclear pore complex alterations in aging and disease. Journal of Cell Science. 2014. ↩︎
Wooley JC, et al. Nucleocytoplasmic transport in aging and neurodegeneration. Mechanisms of Ageing and Development. 2010. ↩︎
Kinoshita M, et al. Nuclear pore complexity in neural cells in aging and disease. Aging Cell. 2022. ↩︎